Conversion from Sandimmune to Neoral in organ transplant recipients. 1998

M R Bartucci, and L Bayer, and B K Brooks, and L Chandler, and V Himes, and D Meiergerd, and B Newby, and N T Satmary, and V Shieck
University Hospital of Cleveland, USA.

The pharmacokinetic profiles of Sandimmune and Neoral vary considerably among transplant recipients. Cyclosporine exposure is far more consistent with Neoral than it is with Sandimmune. Because intrapatient variability of drug exposure has been demonstrated to be a risk factor for chronic rejection, this difference becomes important. Neoral also has a linear dose response and a stronger correlation between trough level and drug exposure. Dose linearity greatly facilitates accurate dose titration. Results of controlled studies in which kidney, liver, and heart transplant recipients were converted from Sandimmune to Neoral have shown that conversion on a 1:1 mg basis results in more predictable bioavailability and often in reductions in cyclosporine dose. Carefully monitored conversion has not been associated with increased side effects, and any side effects that do emerge can usually be managed by taking Neoral with food, changing the dose from every 12 hours to every 8 hours, or through dose reduction.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013810 Therapeutic Equivalency The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease. Bioequivalence,Clinical Equivalency,Equivalency, Therapeutic,Generic Equivalency,Clinical Equivalencies,Equivalencies, Clinical,Equivalencies, Therapeutic,Equivalency, Clinical,Therapeutic Equivalencies,Bioequivalences,Equivalencies, Generic,Equivalency, Generic,Generic Equivalencies
D014181 Transplantation Immunology A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection. Immunology, Transplantation
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400
D016903 Drug Monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug

Related Publications

M R Bartucci, and L Bayer, and B K Brooks, and L Chandler, and V Himes, and D Meiergerd, and B Newby, and N T Satmary, and V Shieck
August 1996, Transplantation proceedings,
M R Bartucci, and L Bayer, and B K Brooks, and L Chandler, and V Himes, and D Meiergerd, and B Newby, and N T Satmary, and V Shieck
June 1999, Transplantation proceedings,
M R Bartucci, and L Bayer, and B K Brooks, and L Chandler, and V Himes, and D Meiergerd, and B Newby, and N T Satmary, and V Shieck
August 1998, Transplantation proceedings,
M R Bartucci, and L Bayer, and B K Brooks, and L Chandler, and V Himes, and D Meiergerd, and B Newby, and N T Satmary, and V Shieck
August 1996, Transplantation proceedings,
M R Bartucci, and L Bayer, and B K Brooks, and L Chandler, and V Himes, and D Meiergerd, and B Newby, and N T Satmary, and V Shieck
June 1997, Journal of transplant coordination : official publication of the North American Transplant Coordinators Organization (NATCO),
M R Bartucci, and L Bayer, and B K Brooks, and L Chandler, and V Himes, and D Meiergerd, and B Newby, and N T Satmary, and V Shieck
April 1997, Revista medica de Chile,
M R Bartucci, and L Bayer, and B K Brooks, and L Chandler, and V Himes, and D Meiergerd, and B Newby, and N T Satmary, and V Shieck
August 1996, Transplantation proceedings,
M R Bartucci, and L Bayer, and B K Brooks, and L Chandler, and V Himes, and D Meiergerd, and B Newby, and N T Satmary, and V Shieck
August 1996, Transplantation proceedings,
M R Bartucci, and L Bayer, and B K Brooks, and L Chandler, and V Himes, and D Meiergerd, and B Newby, and N T Satmary, and V Shieck
December 1995, Transplantation proceedings,
M R Bartucci, and L Bayer, and B K Brooks, and L Chandler, and V Himes, and D Meiergerd, and B Newby, and N T Satmary, and V Shieck
April 1999, Digestive diseases and sciences,
Copied contents to your clipboard!